-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Neuroendocrine Tumors
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Neuroendocrine Tumors report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Neuroendocrine Tumors Drug Details: Voyager-V1 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Metastatic Colorectal Cancer Drug Details: Voyager-V1 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Head And Neck Cancer Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
NewAromatic l-Amino Acid Decarboxylase (AADC) Deficiency – Drugs In Development, 2024
Empower your strategies with our Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency – Drugs In Development, 2024 report and make more profitable business decisions. Aromatic l-amino acid decarboxylase (AADC) deficiency is a disease that affects the production of signals that allow cells in the nervous system to communicate with each other. This is a rare neurotransmitter disorder. AADC is the last enzyme in the biosynthesis of dopamine and serotonin. The deficiency of AADC leads to metabolic disturbance of dopamine, norepinephrine, epinephrine, and...
-
Product Insights
NewProgressive Supranuclear Palsy – Drugs In Development, 2024
Empower your strategies with our Progressive Supranuclear Palsy  – Drugs In Development, 2024 report and make more profitable business decisions. Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome, is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech, and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, and behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications. The Progressive Supranuclear Palsy...
-
Product Insights
NewFriedreich Ataxia – Drugs In Development, 2024
Empower your strategies with our Friedreich Ataxia – Drugs In Development, 2024 report and make more profitable business decisions. Friedreich’s ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties, and diabetes. The Friedreich Ataxia drugs in development market research report provide comprehensive information...
-
Product Insights
NewSpinal Muscular Atrophy (SMA) – Drugs In Development, 2024
Empower your strategies with our Spinal Muscular Atrophy (SMA) – Drugs In Development, 2024 report and make more profitable business decisions. Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important cells are responsible for supplying electrical and chemical messages to muscle cells. Without the proper input from the motor neurons, muscle cells cannot function properly. The muscle cells will, therefore, become much smaller (atrophy) and will produce symptoms...